Fujiwara Motohiro, Komai Yoshinobu, Yuasa Takeshi, Numao Noboru, Yamamoto Shinya, Fukui Iwao, Yonese Junji
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
IJU Case Rep. 2020 Feb 14;3(2):62-64. doi: 10.1002/iju5.12144. eCollection 2020 Mar.
We report the case of a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high who was treated with pembrolizumab after cabazitaxel administration.
A 58-year-old patient with heavily pretreated metastatic castration-resistant prostate cancer, whose prostate surgical specimen was disclosed as microsatellite instability-high, underwent pembrolizumab therapy. After initiation of pembrolizumab, his prostate-specific antigen level decreased, imaging findings showed good response with lymph node shrinkage, and his walking difficulty decreased dramatically.
The rarity of microsatellite instability-high tumor in castration-resistant prostate cancer may hamper pembrolizumab administration. This potentially active agent should be considered as part of a treatment regimen for patients with microsatellite instability-high castration-resistant prostate cancer. To the best of our knowledge, this is the first report of a Japanese castration-resistant prostate cancer patient who demonstrated clinical benefit from pembrolizumab treatment.
我们报告了一例转移性去势抵抗性前列腺癌伴微卫星高度不稳定患者在接受卡巴他赛治疗后使用帕博利珠单抗治疗的病例。
一名58岁的患者，既往有多次治疗史，患有转移性去势抵抗性前列腺癌，其前列腺手术标本显示为微卫星高度不稳定，接受了帕博利珠单抗治疗。开始使用帕博利珠单抗后，他的前列腺特异性抗原水平下降，影像学检查结果显示有良好反应，淋巴结缩小，并且他的行走困难明显减轻。
去势抵抗性前列腺癌中微卫星高度不稳定肿瘤的罕见性可能会阻碍帕博利珠单抗的应用。这种具有潜在活性的药物应被视为微卫星高度不稳定的去势抵抗性前列腺癌患者治疗方案的一部分。据我们所知，这是第一例日本去势抵抗性前列腺癌患者从帕博利珠单抗治疗中获得临床益处的报告。
